William Pao, Vincent A Miller u. a.: Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. In: PLoS Medicine. 2, 2005, S. e73, doi:10.1371/journal.pmed.0020073.
D. A. Cross, S. E. Ashton u. a.: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. In: Cancer Discovery. Band 4, Nummer 9, September 2014, S. 1046–1061, doi:10.1158/2159-8290.CD-14-0337, PMID 24893891, PMC 4315625 (freier Volltext).
T. Stockley, C.A. Souza, et. al.: Evidence-based best practices for EGFR T790M testing in lung cancer in Canada. In: Current Oncology. 25, 2018, S. 163, doi:10.3747/co.25.4044.
Marcel Günther, Michael Juchum, Gerhard Kelter, Heiner Fiebig, Stefan Laufer: Lungenkrebs: EGFR-Inhibitoren mit hoher Wirksamkeit gegen die therapieresistente L858R/T790M/C797S-Mutante.. In: Angewandte Chemie. 128, 2016, S. 11050, doi:10.1002/ange.201603736.
D. A. Cross, S. E. Ashton u. a.: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. In: Cancer Discovery. Band 4, Nummer 9, September 2014, S. 1046–1061, doi:10.1158/2159-8290.CD-14-0337, PMID 24893891, PMC 4315625 (freier Volltext).
